Eye FatigueEye CareNCT07657936
Eye Care Benefits of Anti-Aging Compound Capsules in Healthy Adults
A study testing Anti-Aging Compound Capsules in people with Eye Fatigue, run by China Medical University Hospital at 1 site in Taiwan.
Trial summary
This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks. Read more about this study
- Who is it for?
- Ages 20 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Eye Fatigue
- What is being tested?
- Anti-Aging Compound Capsules
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteTaiwan
- Study dates
- 30 Apr 2026to 10 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 20 to 60 years. Willing to participate in the study and able to provide written informed consent.
- Spherical equivalent refractive error less than 700 diopters of myopia (i.e., < -7.00 D).
Who cannot join
- Regular consumption within the past 1 month of dietary supplements primarily indicated for eye health, or products containing active ocular health-related ingredients that may influence study outcomes (e.g., high-dose lutein ≥10 mg/day or zeaxanthin ≥2 mg/day). Use of general multivitamins or non-eye-specific supplements containing low-dose related ingredients (≤2 mg) may be allowed at the discretion of the investigators.
- History of ocular infection or ocular surgery within the past 3 months. Clinically diagnosed ocular diseases, including but not limited to glaucoma, cataract, age-related macular degeneration, or diabetic retinopathy, or a history of ocular procedures such as cataract surgery, retinal laser therapy, or refractive surgery (e.g., LASIK).
- Known or self-reported hypersensitivity or allergic reaction to any component of the investigational product, including but not limited to fish oil, soybean-derived products, gelatin (bovine source), yeast, or any other listed ingredients.
- Individuals with direct affiliation, supervisory, evaluative, or dependent relationships with the research team, including but not limited to:
- Students taught, supervised, or evaluated by members of the research team; Laboratory or research assistants, staff, or collaborators within the same research unit; Interns, part-time workers, or employees under the supervision of the research team.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Exploring the Eye Care Benefits of Anti-aging Compound Capsules
This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks.
The primary outcome is the improvement of ocular discomfort and eye fatigue symptoms assessed using the Ocular Surface Disease Index (OSDI). Secondary outcomes include visual acuity, accommodative function, tear film stability, macular pigment optical density, intraocular pressure, and photostress recovery time. The study will investigate whether daily supplementation with anti-aging compound capsules can improve visual comfort and support ocular health.
Read the detailed description
Visual fatigue and ocular discomfort have become increasingly prevalent due to prolonged use of digital devices, environmental stressors, and age-related changes in visual function. Nutritional supplementation containing antioxidants, carotenoids, omega-3 fatty acids, vitamins, minerals, and other bioactive compounds may help maintain ocular health and visual performance.
This prospective, single-arm, open-label clinical study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Twenty-five participants will be enrolled and instructed to consume anti-aging compound capsules for four consecutive weeks.
Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.
Participants will consume two capsules twice daily for a total daily intake of 2,200 mg. Ophthalmic assessments will be performed at baseline, Week 2, and Week 4.
The primary outcome measure is the Ocular Surface Disease Index (OSDI) score. Secondary outcome measures include distance visual acuity, near visual acuity, accommodative response, accommodative facility, tear film break-up time, macular pigment optical density, intraocular pressure, and photostress recovery time.
The study aims to determine whether supplementation with anti-aging compound capsules can improve eye fatigue symptoms and support ocular health in healthy adults.
- Conditions
- Eye Fatigue
- Being tested
- Anti-Aging Compound Capsules
- Keywords
- Eye Fatigue, Visual Function, Dry Eye Symptoms
- Medical subject headings
- Asthenopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anti-Aging Compound CapsulesDietary supplement
Participants will consume anti-aging compound capsules twice daily for 4 weeks. Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters. Total daily intake is 2,200 mg.
| Study group | Role | What they receive |
|---|---|---|
| Anti-Aging Compound Capsules | Experimental | Participants will receive anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for 4 weeks. Participants will take 2 capsules twice daily (total daily dose 2,200 mg). Receives: Dietary Supplement: Anti-Aging Compound Capsules |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Ocular Surface Disease Index (OSDI) Score
Changes in ocular discomfort and eye fatigue symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire. The OSDI is a validated 12-item questionnaire used to evaluate symptoms related to ocular surface disease and visual function. Assessments will be performed at baseline, Week 2, and Week 4. A decrease in OSDI score indicates improvement in ocular symptoms.
Measured: baseline / week2 / week4
Change in Distance Visual Acuity (DVA, logMAR)
Changes in distance visual acuity will be measured using a Snellen chart at 6 meters and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. Assessments will be performed at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Change in Near Visual Acuity (NVA)
Changes in near visual acuity will be assessed using a Snellen near-vision chart at a distance of 40 cm. Assessments will be performed at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Change in Accommodative Response
Accommodative response will be measured using a Shin-Nippon NVision-K5001 open-field autorefractor, including accommodative lag and accommodative lead. Measurements will be conducted at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Change in Accommodative Facility (cycles per minute)
Accommodative facility will be assessed using ±0.50 diopter flipper lenses with standard accommodative targets. Results will be recorded as cycles per minute (CPM). Assessments will be performed at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Change in Tear Film Break-Up Time (TBUT)
Tear film stability will be evaluated using non-invasive tear break-up time measured by a corneal topography system (Topcon CA-800). Assessments will be conducted at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Change in Macular Pigment Optical Density (MPOD)
Macular pigment optical density will be measured using a macular pigment optical density analyzer. Assessments will be performed at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Change in Photostress Recovery Time
Photostress recovery time will be assessed by measuring the time required for visual function to return to baseline following exposure to a standardized bright light stimulus. Assessments will be performed at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Secondary outcomes (1)
Change in Intraocular Pressure (IOP)
Intraocular pressure will be measured using non-contact tonometry. Measurements will be performed at baseline, Week 2, and Week 4.
Measured: baseline / week2 / week4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2026
- Study start30 Apr 2026
- Primary completion3 Jun 2026
- Study completion10 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Eye FatigueStudies of the same condition, open and under way.
- More trials run by China Medical University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- China Medical University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hui Wen Lin, Chung Shan Medical University
- Investigators
- Lin, associated professor, Principal investigator, Institute of Medical Research, Chung Shan Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07657936
- Sponsor's protocol ID
- CS1-25234
- Acronym
- Eye Care
- Status last verified
- Jun 2026
- First submitted
- 14 Jun 2026
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared due to ethical and privacy considerations. The dataset includes ophthalmic measurements and health-related questionnaire data that could potentially identify participants. Data may be available upon reasonable request and with approval from the corresponding ethics committee.
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Eye Care Benefits of Anti-aging Compound Capsules
- ClinicalTrials.gov ID
- NCT07657936
- Acronym / sponsor ID
- Eye Care / CS1-25234
- Conditions
- Eye Fatigue
- Keywords
- Eye Fatigue, Visual Function, Dry Eye Symptoms
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- China Medical University HospitalUniversity, hospital or other
- Study start
- 30 Apr 2026 (actual)
- Primary completion
- 3 Jun 2026 (actual)
- Study completion
- 10 Jun 2026 (actual)
- First posted
- 18 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks.
The primary outcome is the improvement of ocular discomfort and eye fatigue symptoms assessed using the Ocular Surface Disease Index (OSDI). Secondary outcomes include visual acuity, accommodative function, tear film stability, macular pigment optical density, intraocular pressure, and photostress recovery time. The study will investigate whether daily supplementation with anti-aging compound capsules can improve visual comfort and support ocular health.
Detailed description
Visual fatigue and ocular discomfort have become increasingly prevalent due to prolonged use of digital devices, environmental stressors, and age-related changes in visual function. Nutritional supplementation containing antioxidants, carotenoids, omega-3 fatty acids, vitamins, minerals, and other bioactive compounds may help maintain ocular health and visual performance.
This prospective, single-arm, open-label clinical study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Twenty-five participants will be enrolled and instructed to consume anti-aging compound capsules for four consecutive weeks.
Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.
Participants will consume two capsules twice daily for a total daily intake of 2,200 mg. Ophthalmic assessments will be performed at baseline, Week 2, and Week 4.
The primary outcome measure is the Ocular Surface Disease Index (OSDI) score. Secondary outcome measures include distance visual acuity, near visual acuity, accommodative response, accommodative facility, tear film break-up time, macular pigment optical density, intraocular pressure, and photostress recovery time.
The study aims to determine whether supplementation with anti-aging compound capsules can improve eye fatigue symptoms and support ocular health in healthy adults.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Anti-Aging Compound Capsules | Experimental | Dietary Supplement: Anti-Aging Compound CapsulesParticipants will receive anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for 4 weeks. Participants will take 2 capsules twice daily (total daily dose 2,200 mg). |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Adults aged 20 to 60 years. Willing to participate in the study and able to provide written informed consent.
- Spherical equivalent refractive error less than 700 diopters of myopia (i.e., < -7.00 D).
Key exclusion criteria (5 listed)
- Regular consumption within the past 1 month of dietary supplements primarily indicated for eye health, or products containing active ocular health-related ingredients that may influence study outcomes (e.g., high-dose lutein ≥10 mg/day or zeaxanthin ≥2 mg/day). Use of general multivitamins or non-eye-specific supplements containing low-dose related ingredients (≤2 mg) may be allowed at the discretion of the investigators.
- History of ocular infection or ocular surgery within the past 3 months. Clinically diagnosed ocular diseases, including but not limited to glaucoma, cataract, age-related macular degeneration, or diabetic retinopathy, or a history of ocular procedures such as cataract surgery, retinal laser therapy, or refractive surgery (e.g., LASIK).
- Known or self-reported hypersensitivity or allergic reaction to any component of the investigational product, including but not limited to fish oil, soybean-derived products, gelatin (bovine source), yeast, or any other listed ingredients.
- Individuals with direct affiliation, supervisory, evaluative, or dependent relationships with the research team, including but not limited to:
- Students taught, supervised, or evaluated by members of the research team; Laboratory or research assistants, staff, or collaborators within the same research unit; Interns, part-time workers, or employees under the supervision of the research team.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anti-Aging Compound CapsulesParticipants will consume anti-aging compound capsules twice daily for 4 weeks. Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters. Total daily intake is 2,200 mg. | Dietary supplement | Anti-Aging Compound Capsules |
Primary outcome
Change in Ocular Surface Disease Index (OSDI) Score
Time frame: baseline / week2 / week4
Changes in ocular discomfort and eye fatigue symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire. The OSDI is a validated 12-item questionnaire used to evaluate symptoms related to ocular surface disease and visual function. Assessments will be performed at baseline, Week 2, and Week 4. A decrease in OSDI score indicates improvement in ocular symptoms.
Change in Distance Visual Acuity (DVA, logMAR)
Time frame: baseline / week2 / week4
Changes in distance visual acuity will be measured using a Snellen chart at 6 meters and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. Assessments will be performed at baseline, Week 2, and Week 4.
Change in Near Visual Acuity (NVA)
Time frame: baseline / week2 / week4
Changes in near visual acuity will be assessed using a Snellen near-vision chart at a distance of 40 cm. Assessments will be performed at baseline, Week 2, and Week 4.
Change in Accommodative Response
Time frame: baseline / week2 / week4
Accommodative response will be measured using a Shin-Nippon NVision-K5001 open-field autorefractor, including accommodative lag and accommodative lead. Measurements will be conducted at baseline, Week 2, and Week 4.
Change in Accommodative Facility (cycles per minute)
Time frame: baseline / week2 / week4
Accommodative facility will be assessed using ±0.50 diopter flipper lenses with standard accommodative targets. Results will be recorded as cycles per minute (CPM). Assessments will be performed at baseline, Week 2, and Week 4.
Change in Tear Film Break-Up Time (TBUT)
Time frame: baseline / week2 / week4
Tear film stability will be evaluated using non-invasive tear break-up time measured by a corneal topography system (Topcon CA-800). Assessments will be conducted at baseline, Week 2, and Week 4.
Change in Macular Pigment Optical Density (MPOD)
Time frame: baseline / week2 / week4
Macular pigment optical density will be measured using a macular pigment optical density analyzer. Assessments will be performed at baseline, Week 2, and Week 4.
Change in Photostress Recovery Time
Time frame: baseline / week2 / week4
Photostress recovery time will be assessed by measuring the time required for visual function to return to baseline following exposure to a standardized bright light stimulus. Assessments will be performed at baseline, Week 2, and Week 4.
1 secondary outcome
Change in Intraocular Pressure (IOP)
Time frame: baseline / week2 / week4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared due to ethical and privacy considerations. The dataset includes ophthalmic measurements and health-related questionnaire data that could potentially identify participants. Data may be available upon reasonable request and with approval from the corresponding ethics committee.
Related trials for Eye Fatigue
Recruiting
Lactic Acid Bacteria for Reducing Blue Light-Induced Eye Fatigue
Digital Eye Strain (DES)
Not yet recruiting
Comparative Effects of Exercises on Pain, Cervical Proprioception, Neck Disability and Visual Performance in Patients With Computer Vision Syndrome.
Computer Vision Syndrome
RecruitingPhase 3
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Sjögren´s Disease
Not yet recruitingPhase 1/2
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Recruiting
Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies
Sjogren Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lin, associated professor principal investigator
Institute of Medical Research, Chung Shan Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Anti-Aging Compound Capsules in people with Eye Fatigue, run by China Medical University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Ocular Surface Disease Index (OSDI) Score (time frame: baseline / week2 / week4). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.